On January 21, 2026, Badreddin Edris, a director at Edgewise Therapeutics, Inc. (NASDAQ:EWTX), executed a sale of 115,471 shares of the company's common stock. The transaction generated proceeds close to $3.39 million, with shares sold at prices ranging between $29.00 and $29.77, culminating in a weighted average sale price of approximately $29.44 per share. This disposition was carried out according to a pre-established Rule 10b5-1 trading plan initiated on September 24, 2025.
Simultaneously, Edris engaged in the exercise of stock options on the same date, resulting in the purchase of 115,461 shares of Edgewise Therapeutics common stock. The options were exercised at prices spanning from $0.39 to $1.93 per share, incurring an aggregate payment of $170,263. Following these exercises and sales, Edris retains direct ownership of 19,820 shares in the company.
Concurrently with these insider transactions, Edgewise Therapeutics shared positive interim safety insights from its ongoing Phase 2 clinical trial evaluating EDG-7500, its therapeutic candidate for hypertrophic cardiomyopathy. The company reported favorable tolerability across trial participants and notably did not observe any clinically meaningful declines in left ventricular ejection fraction, a critical measure of cardiac function. This outcome potentially differentiates EDG-7500 from other therapies in the market that have been linked to systolic dysfunction.
In addition to these clinical updates, Edgewise Therapeutics has fortified its leadership team with key appointments. Christopher Martin, formerly Chief Commercial Officer at Verona Pharma, has joined the Board of Directors, contributing his commercial expertise. Furthermore, Michael Nofi was named Chief Financial Officer, succeeding R. Michael Carruthers. Nofi arrives from SpringWorks Therapeutics, where he served as Chief Accounting Officer.
Market analysts have taken note of these developments. Truist Securities has reiterated a Buy rating for Edgewise Therapeutics, highlighting an attractive risk/reward profile in anticipation of forthcoming data releases. Collectively, the insider transactions, leadership enhancements, and positive clinical data signal strategic momentum for the biotechnology company.